| 3.855 0.005 (0.13%) | 05-08 13:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.95 | 1-year : | 5.45 |
| Resists | First : | 4.24 | Second : | 4.67 |
| Pivot price | 3.84  |
|||
| Supports | First : | 3.54 | Second : | 2.95 |
| MAs | MA(5) : | 3.81  |
MA(20) : | 3.92 |
| MA(100) : | 4.36 |
MA(250) : | 3.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 47.2 |
D(3) : | 37.1 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 6.3 | Low : | 1.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NGEN ] has closed below upper band by 41.5%. Bollinger Bands are 57.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.95 - 3.98 | 3.98 - 3.99 |
| Low: | 3.75 - 3.77 | 3.77 - 3.79 |
| Close: | 3.81 - 3.85 | 3.85 - 3.89 |
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
Mon, 20 Apr 2026
NervGen (NGEN) Stock Initiates Position (Near Lows) 2026-04-20 - Risk Analysis - UBND thành phố Hải Phòng
Wed, 15 Apr 2026
NervGen (NGEN) Stock: Why Short Sellers Target It (+1.19%) 2026-04-15 - Volume Breakout - Cổng thông tin điện tử Tỉnh Sơn La
Wed, 01 Apr 2026
NGEN Stock Analysis: NervGen Pharma Corp. Common stock gains 4.24% at 3.93 dollars - UBND thành phố Hải Phòng
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 81 (M) |
| Held by Insiders | 6.891e+007 (%) |
| Held by Institutions | 20.7 (%) |
| Shares Short | 1,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.502e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -73.5 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 462.19 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 128.14 |
| Dividend | 0 |
| Forward Dividend | 1.43e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|